Immunomatics

About the offering

Immunomatics is an early-stage AI software company based in San Marcos, CA, focused on reducing organ transplant rejection. The company was founded by Lidio Meireles, a stem cell transplant survivor with a PhD and MS in computational biology and AI, who also has experience contributing to FDA-approved therapeutics at Vertex Pharmaceuticals. The core problem Immunomatics addresses is that current donor selection for kidney transplants relies on counting HLA mismatches without distinguishing which mismatches are clinically tolerable versus which drive rejection — a blunt approach that contribuates to roughly 1 in 5 kidney transplants failing within five years. Immunomatics is developing an AI-powered rejection-risk scoring platform that analyzes donor and recipient genetic data to produce a pre-transplant risk score. The platform is designed to integrate into existing transplant workflows using data already collected, rather than requiring new data collection. The intended clinical applications include safer donor selection, personalized immunosuppression dosing, and more effective rejection monitoring. Key credibility markers include a $207,740 NIH Phase I SBIR grant (non-dilutive), which provides third-party scientific validation. The company has a collaboration with UC San Diego's Immunogenetics & Transplantation Lab and access to SRTR (Scientific Registry of Transplant Recipients) data. The team also includes Senior AI Scientist Tonislav Ivanov (10+ years in deep learning across aerospace, healthcare, and semiconductors) and AI Scientist David De Oliveira Lima, who specializes in deep learning for biomedical applications including computational histopathology for renal assessment. The company is raising $500,000 via a SAFE instrument with a 20% discount and an $8M post-money valuation cap. Proceeds are intended to advance the platform through proof of concept and early clinical validation. As of the campaign snapshot, $53,960 had been raised from 44 investors on Wefunder, with a minimum investment of $100. The company is at an early stage and carries scientific, regulatory, execution, and commercialization risks.

FAQ